To address this, we measured HOXB13 expression by immunohistochemistry (IHC) in an Emory University cohort (Emory cohort) that consisted of 56 high-grade primary PCa cases and 56 lymph node–metastatic (LN-metastatic) PCa cases, all from patients with no prior history of hormone therapy, that is, hormone-naive (HN). The gene discussed is HOXB13; the disease is posterior cortical atrophy.